Lantheus Announces Executive Appointments to Accelerate Innovation
May 15 2024 - 4:30PM
Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading
radiopharmaceutical-focused company committed to enabling
clinicians to Find, Fight and Follow disease to deliver better
patient outcomes, today announced Jeffrey S. Humphrey, MD has been
appointed Chief Medical Officer (CMO) and Jean-Claude Provost, MD
has been named Chief Science Officer (CSO), effective May 28, 2024.
“Jeff’s clinical oncology expertise and leadership will bring
immense value to Lantheus as we strengthen our position as the
leading radiopharmaceutical-focused company through sustained
innovation in diagnostics and therapeutics,” said Brian Markison,
Chief Executive Officer, Lantheus. “Jean-Claude’s deep
radiopharmaceutical knowledge and experience with the Lantheus team
will be invaluable in his new role as CSO, as we execute our
business development strategy to enhance our pipeline and
capabilities. These moves will enable our team to accelerate
innovation.”
Dr. Humphrey is a seasoned leader in drug development and a
physician-scientist with more than 30 years of experience in
clinical oncology, neuroscience, cancer research, and drug
discovery, having led organizations developing drugs from pre-IND
through launch. As CMO, he will oversee Lantheus’ research and
development organization, including research and pharmaceutical
development, regulatory affairs, clinical development, medical
affairs, and isotope strategy. Dr. Humphrey spent more than two
decades working for global pharmaceutical companies, including
Bayer, Bristol-Myers Squibb, Kyowa Kirin, and Pfizer, and
subsequently held senior leadership positions at multiple
clinical-stage biotechnology companies. Dr. Humphrey earned a
Doctorate in Medicine from Case Western Reserve University School
of Medicine and an AB in Applied Mathematics from Harvard
University. He is Board Certified in Oncology and Internal Medicine
and has published more than 30 peer-reviewed papers in molecular
biology and clinical research.
“As I take on the CMO role at Lantheus, I am excited to combine
my passion for advancing patient care and developing talented team
members with my broad knowledge of oncology drug development to
contribute to Lantheus, a company dedicated to delivering better
patient outcomes and shaping the future of diagnostic and
therapeutic radiopharmaceuticals,” said Dr. Humphrey.
Dr. Jean-Claude Provost, in his new CSO role, will support
Lantheus’ business development activities to advance and enhance
the Company’s pipeline and capabilities. Dr. Provost offers a
wealth of scientific acumen, extensive research and development
experience, and deep radiopharmaceutical and industry knowledge.
Dr. Provost has more than thirty years of experience in the
international development of therapeutic drugs and diagnostic
agents for global companies, including GE Healthcare’s
pharmaceutical diagnostics division, Pfizer, Merck-Serono and
Bayer. Dr. Provost holds degrees in Methodology and Statistics and
Clinical Pharmacology from the University of Paris and a Doctorate
in Medicine from Sorbonne University, Paris.
About LantheusLantheus is the leading
radiopharmaceutical-focused company, delivering life-changing
science to enable clinicians to Find, Fight and Follow disease to
deliver better patient outcomes. Headquartered in Massachusetts
with offices in Canada and Sweden, Lantheus has been providing
radiopharmaceutical solutions for more than 65 years. For more
information, visit www.lantheus.com.
Safe Harbor for Forward-Looking and Cautionary
StatementsThis press release contains “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, that are subject to risks and
uncertainties and are made pursuant to the safe harbor provisions
of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements may be identified by their use of terms
such as “continue,” “enhance,” “expand,” “focus,“ “look,” “will”
and other similar terms. Such forward-looking statements are based
upon current plans, estimates and expectations that are subject to
risks and uncertainties that could cause actual results to
materially differ from those described in the forward-looking
statements. The inclusion of forward-looking statements should not
be regarded as a representation that such plans, estimates and
expectations will be achieved. Readers are cautioned not to place
undue reliance on the forward-looking statements contained herein,
which speak only as of the date hereof. The Company undertakes no
obligation to publicly update any forward-looking statement,
whether as a result of new information, future developments or
otherwise, except as may be required by law. Risks and
uncertainties that could cause our actual results to materially
differ from those described in the forward-looking statements are
discussed in our filings with the Securities and Exchange
Commission (including those described in the Risk Factors section
in our Annual Reports on Form 10-K and our Quarterly Reports on
Form 10-Q).
Contacts:
LantheusMark KinarneyVice President, Investor
Relations978-671-8842ir@lantheus.com
Melissa DownsSenior Director, External
Communications646-975-2533media@lantheus.com
Lantheus (NASDAQ:LNTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lantheus (NASDAQ:LNTH)
Historical Stock Chart
From Jul 2023 to Jul 2024